DXCM vs. EXAS

Last updated Jun 4, 2026

DXCM (DexCom, Inc.) and EXAS (Exact Sciences Corporation) are both stocks. Both operate in the Diagnostics & Research industry within the Healthcare sector. At a 0.28 correlation, their price movements are largely independent.

Performance

DXCM vs. EXAS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in DexCom, Inc. (DXCM) and Exact Sciences Corporation (EXAS). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

DXCM

• 1D: -0.93%
• 1M: 21.20%
• YTD: 9.64%
• 6M: 12.21%
• 1Y: -16.15%
• 3Y*: -15.95%
• 5Y*: -5.34%
• 10Y*: 15.73%

EXAS

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

DXCM vs. EXAS - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
DXCM DexCom, Inc.	9.64%	-14.66%	-37.33%	9.58%	-15.64%	45.23%	69.02%	82.59%	108.75%	-3.87%
EXAS Exact Sciences Corporation	3.30%	80.74%	-24.05%	49.42%	-36.39%	-41.26%	43.26%	46.56%	20.10%	293.26%

Correlation

The correlation between DXCM and EXAS is 0.16, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.16
Correlation (3Y) Calculated over the trailing 3-year period	0.25
Correlation (5Y) Calculated over the trailing 5-year period	0.37
Correlation (10Y) Calculated over the trailing 10-year period	0.38
Correlation (All Time) Calculated using the full available price history since Apr 15, 2005	0.28

The correlation between DXCM and EXAS shifts across timeframes, from 0.16 (1 year) to 0.38 (10 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap DXCM : $28.64B EXAS : $19.91B
EPS DXCM : $2.31 EXAS : -$1.10
PS Ratio DXCM : 6.07 EXAS : 6.12
PB Ratio DXCM : 9.69 EXAS : 8.29
Total Revenue (TTM) DXCM : $4.82B EXAS : $3.25B
Gross Profit (TTM) DXCM : $2.96B EXAS : $2.26B
EBITDA (TTM) DXCM : $1.37B EXAS : $42.61M

Return for Risk

DXCM vs. EXAS — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

DXCM

DXCM Risk / Return Rank: 24
DXCM Sharpe Ratio Rank: 23
DXCM Sortino Ratio Rank: 23
DXCM Omega Ratio Rank: 22
DXCM Calmar Ratio Rank: 26
DXCM Martin Ratio Rank: 27

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

DXCM vs. EXAS - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for DexCom, Inc. (DXCM) and Exact Sciences Corporation (EXAS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	DXCM	EXAS	Difference
Sharpe ratio: Return per unit of total volatility	-0.40	—	—
Sortino ratio: Return per unit of downside risk	-0.31	—	—
Omega ratio: Gain probability vs. loss probability	0.96	—	—
Calmar ratio: Return relative to maximum drawdown	-0.42	—	—
Martin ratio: Return relative to average drawdown	-0.72	—	—
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

Sharpe Ratios by Period

	DXCM	EXAS	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.40	—	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.11	—	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.33	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.30	—	—

Drawdowns

Drawdown Indicators

	DXCM	EXAS	Difference
Max Drawdown Largest peak-to-trough decline	-94.61%	—	—
Max Drawdown (1Y) Largest decline over 1 year	-38.75%	—	—
Max Drawdown (3Y) Largest decline over 3 years	-60.95%	—	—
Max Drawdown (5Y) Largest decline over 5 years	-66.32%	—	—
Max Drawdown (10Y) Largest decline over 10 years	-66.32%	—	—
Current Drawdown Current decline from peak	-55.31%	—	—
Average Drawdown Average peak-to-trough decline	-35.99%	—	—
Ulcer Index Depth and duration of drawdowns from previous peaks	22.63%	—	—

Volatility

Volatility by Period

	DXCM	EXAS	Difference
Volatility (1M) Calculated over the trailing 1-month period	13.22%	—	—
Volatility (6M) Calculated over the trailing 6-month period	24.61%	—	—
Volatility (1Y) Calculated over the trailing 1-year period	40.26%	—	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	46.91%	—	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	48.43%	—	—

Dividends

DXCM vs. EXAS - Dividend Comparison

Neither DXCM nor EXAS has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

DXCM vs. EXAS - Profitability Comparison

The chart below illustrates the profitability comparison between DexCom, Inc. and Exact Sciences Corporation over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

DXCM - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, DexCom, Inc. reported a gross profit of 750.30M and revenue of 1.19B. Therefore, the gross margin over that period was 63.0%.

EXAS - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Exact Sciences Corporation reported a gross profit of 615.83M and revenue of 878.38M. Therefore, the gross margin over that period was 70.1%.

DXCM - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, DexCom, Inc. reported an operating income of 255.30M and revenue of 1.19B, resulting in an operating margin of 21.4%.

EXAS - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Exact Sciences Corporation reported an operating income of -76.68M and revenue of 878.38M, resulting in an operating margin of -8.7%.

DXCM - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, DexCom, Inc. reported a net income of 199.50M and revenue of 1.19B, resulting in a net margin of 16.7%.

EXAS - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Exact Sciences Corporation reported a net income of -85.96M and revenue of 878.38M, resulting in a net margin of -9.8%.

Frequently Asked Questions

Can I hold both DXCM and EXAS in my portfolio?

DXCM and EXAS have a correlation of 0.16, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.